» Articles » PMID: 30195724

CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo

Overview
Journal Mol Ther
Publisher Cell Press
Date 2018 Sep 10
PMID 30195724
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD), a severe hereditary disease affecting 1 in 3,500 boys, mainly results from the deletion of exon(s), leading to a reading frameshift of the DMD gene that abrogates dystrophin protein synthesis. Pairs of sgRNAs for the Cas9 of Staphylococcus aureus were meticulously chosen to restore a normal reading frame and also produce a dystrophin protein with normally phased spectrin-like repeats (SLRs), which is not usually obtained by skipping or by deletion of complete exons. This can, however, be obtained in rare instances where the exon and intron borders of the beginning and the end of the complete deletion (patient deletion plus CRISPR-induced deletion) are at similar positions in the SLR. We used pairs of sgRNAs targeting exons 47 and 58, and a normal reading frame was restored in myoblasts derived from muscle biopsies of 4 DMD patients with different exon deletions. Restoration of the DMD reading frame and restoration of dystrophin expression were also obtained in vivo in the heart of the del52hDMD/mdx. Our results provide a proof of principle that SaCas9 could be used to edit the human DMD gene and could be considered for further development of a therapy for DMD.

Citing Articles

Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications.

Wu Y, Chen J, Jong Y J Biomed Sci. 2025; 32(1):30.

PMID: 39985020 PMC: 11844187. DOI: 10.1186/s12929-025-01123-z.


Targeting EP2 Receptor Improves Muscle and Bone Health in Dystrophin/Utrophin Double-Knockout Mice.

Gao X, Cui Y, Zhang G, Ruzbarsky J, Wang B, Layne J Cells. 2025; 14(2).

PMID: 39851544 PMC: 11763967. DOI: 10.3390/cells14020116.


CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.

Laurent M, Geoffroy M, Pavani G, Guiraud S Cells. 2024; 13(10.

PMID: 38786024 PMC: 11119143. DOI: 10.3390/cells13100800.


Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.

Szwec S, Kaplucha Z, Chamberlain J, Konieczny P BioDrugs. 2023; 38(1):95-119.

PMID: 37917377 PMC: 10789850. DOI: 10.1007/s40259-023-00632-3.


CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein.

Egorova T, Polikarpova A, Vassilieva S, Dzhenkova M, Savchenko I, Velyaev O Mol Ther Methods Clin Dev. 2023; 30:161-180.

PMID: 37457303 PMC: 10339130. DOI: 10.1016/j.omtm.2023.06.006.


References
1.
El Refaey M, Xu L, Gao Y, Canan B, Adesanya T, Warner S . In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. Circ Res. 2017; 121(8):923-929. PMC: 5623072. DOI: 10.1161/CIRCRESAHA.117.310996. View

2.
t Hoen P, de Meijer E, Boer J, Vossen R, Turk R, Maatman R . Generation and characterization of transgenic mice with the full-length human DMD gene. J Biol Chem. 2007; 283(9):5899-907. DOI: 10.1074/jbc.M709410200. View

3.
Brinkman E, Chen T, Amendola M, van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42(22):e168. PMC: 4267669. DOI: 10.1093/nar/gku936. View

4.
Iyombe-Engembe J, Ouellet D, Barbeau X, Rousseau J, Chapdelaine P, Lague P . Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method. Mol Ther Nucleic Acids. 2016; 5:e283. PMC: 5012554. DOI: 10.1038/mtna.2015.58. View

5.
Dai X, Chen X, Fang Q, Li J, Bai Z . Inducible CRISPR genome-editing tool: classifications and future trends. Crit Rev Biotechnol. 2017; 38(4):573-586. DOI: 10.1080/07388551.2017.1378999. View